Last reviewed · How we verify
Lanreotide ATG
Lanreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone and other hormones.
Lanreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone and other hormones. Used for Acromegaly, Neuroendocrine tumors (carcinoid syndrome), Gastroenteropancreatic neuroendocrine tumors.
At a glance
| Generic name | Lanreotide ATG |
|---|---|
| Sponsor | Camurus AB |
| Drug class | Somatostatin analog |
| Target | Somatostatin receptors (SSTR2, SSTR5) |
| Modality | Small molecule |
| Therapeutic area | Oncology / Endocrinology |
| Phase | Phase 3 |
Mechanism of action
Lanreotide mimics somatostatin, a natural inhibitory hormone, by binding to somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine cells. This suppresses the release of growth hormone, insulin-like growth factor-1 (IGF-1), and other hormones, thereby reducing symptoms and tumor growth in neuroendocrine disorders. The ATG formulation (autogel) is a long-acting depot injection designed for extended drug release.
Approved indications
- Acromegaly
- Neuroendocrine tumors (carcinoid syndrome)
- Gastroenteropancreatic neuroendocrine tumors
Common side effects
- Diarrhea
- Abdominal pain
- Nausea
- Injection site reactions
- Gallstones (cholelithiasis)
- Hyperglycemia
Key clinical trials
- A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (PHASE1)
- A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET (PHASE3)
- Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy (PHASE4)
- The MetNET-2 Trial (EARLY_PHASE1)
- Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors. (PHASE2)
- Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG) (PHASE2)
- Somatuline Predictive Factors in Acromegaly and NET
- Predictive Factors Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |